Amylyx Pharmaceuticals Dirección
Dirección controles de criterios 3/4
Amylyx Pharmaceuticals' El consejero delegado es Josh Cohen , nombrado en Jan 2013, tiene un mandato de 11.08 años. la remuneración anual total es $7.18M , compuesta por 7.5% salario y 92.5% primas, incluidas acciones y opciones de la empresa. posee directamente 4.17% de las acciones de la empresa, por valor de $45.01M . La antigüedad media del equipo directivo y del consejo de administración es de 3.3 años y 4.8 años respectivamente.
Información clave
Josh Cohen
Chief Executive Officer (CEO)
US$7.2m
Compensación total
| Porcentaje del salario del CEO | 7.5% |
| Permanencia del CEO | 11.3yrs |
| Participación del CEO | 4.1% |
| Permanencia media de la dirección | 3.3yrs |
| Promedio de permanencia en la Junta Directiva | 3.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically
Mar 12
An ALS Drug Fails Again
Mar 09Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
Feb 23Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues
Feb 23Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper
Nov 10Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Sep 24This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year
May 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Apr 20Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates
Mar 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans
Dec 19Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share
Oct 07Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis
Sep 30Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing
Sep 08Amylyx plunges 28% after FDA briefing documents on ALS drug
Sep 02We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
Aug 29Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01
Aug 11Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada
Jul 29Amylyx partners with Sunnybrook Research to identify neurodegenerative disease candidates
Jul 18Amylyx: Thoughts Ahead Of September 29 PDUFA In Amyotrophic Lateral Sclerosis
Jul 04Amylyx Pharmaceuticals: Share Price Bump On Canada Approval For ALS Drug May Not Last
Jun 17We're Keeping An Eye On Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
May 07Amylyx: Crucial Advisory Committee Meet Tomorrow, Approval Chancy
Mar 29Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | US$49m |
| Sep 30 2023 | n/a | n/a | US$2m |
| Jun 30 2023 | n/a | n/a | -US$73m |
| Mar 31 2023 | n/a | n/a | -US$149m |
| Dec 31 2022 | US$7m | US$539k | -US$198m |
| Sep 30 2022 | n/a | n/a | -US$184m |
| Jun 30 2022 | n/a | n/a | -US$153m |
| Mar 31 2022 | n/a | n/a | -US$121m |
| Dec 31 2021 | US$1m | US$418k | -US$88m |
| Sep 30 2021 | n/a | n/a | -US$68m |
| Dec 31 2020 | US$671k | US$370k | -US$42m |
Compensación vs. Mercado: Josh($USD7.18M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.42M).
Compensación vs. Ingresos: La compensación de Josh ha sido consistente con los resultados de la empresa en el último año.
CEO
Josh Cohen (31 yo)
11.3yrs
Permanencia
US$7,178,416
Compensación
Mr. Joshua B. Cohen also known as Josh, co-founded Amylyx Pharmaceuticals, Inc. in 2013 and has been its Co-Chief Executive Officer and Director since January 2014. Mr. Cohen served as Chairman of the Boar...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 11.3yrs | US$7.18m | 4.14% $ 7.6m | |
| Co-Founder | 11.3yrs | US$7.18m | 4.05% $ 7.4m | |
| Chief Financial Officer | 3.3yrs | US$3.66m | 0.12% $ 225.5k | |
| Chief Legal Officer & General Counsel | 2.2yrs | US$6.11m | 0.0087% $ 15.8k | |
| Chief Technical Operations Officer | no data | sin datos | sin datos | |
| Head of Investor Relations & Communications | no data | sin datos | sin datos | |
| Head of Global Marketing | 3.3yrs | sin datos | sin datos | |
| Chief Human Resources Officer | less than a year | sin datos | sin datos | |
| Head of Canada & GM | 3yrs | sin datos | sin datos | |
| Head of Global Market Access | 3.3yrs | sin datos | sin datos | |
| Global Head of Regulatory Affairs | 3.7yrs | sin datos | sin datos | |
| VP & Head of Global Medical Affairs | 3.9yrs | sin datos | sin datos |
3.3yrs
Permanencia media
42yo
Promedio de edad
Equipo directivo experimentado: AMLXEl equipo directivo de la empresa se considera experimentado (3.8 años de antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 10.3yrs | US$7.18m | 4.14% $ 7.6m | |
| Co-Founder | 10.3yrs | US$7.18m | 4.05% $ 7.4m | |
| Company Secretary & Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Special Advisor & Member of Advisory Board | 3.3yrs | US$51.24k | sin datos | |
| Independent Chairman of the Board | 9.3yrs | US$386.85k | 1.12% $ 2.0m | |
| Chairman of The Scientific Advisory Board | no data | sin datos | sin datos | |
| Board Observer & Advisor | 6.8yrs | sin datos | sin datos | |
| Independent Director | 1.1yrs | sin datos | 0.0074% $ 13.5k | |
| Independent Director | 2.8yrs | US$352.09k | 0% $ 0 | |
| Director | less than a year | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 3.1yrs | US$354.15k | 0.0058% $ 10.6k |
3.3yrs
Permanencia media
61.5yo
Promedio de edad
Junta con experiencia: La junta directiva de AMLX se considera experimentada (4.7 años de antigüedad promedio).